PARIS--(BUSINESS WIRE)--NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage French nanomedicine company (the “Company”) working on the local treatment of cancer, and listed on Euronext, Paris, announced the completion of a private placement on November 24, 2014.
The private placement was carried out in accordance with applicable French and U.S. private placement exemptions, and has been made with Capital Ventures International (“CVI”), a U.S. investor, and includes the following securities and terms:
• purchase by the investor of 650,000 new shares (the “New Shares”) (with 650,000 warrants attached) of the Company for a total subscription amount of €10,393,500, representing around 4.85% of the Company’s outstanding shares prior to the private placement;
Help employers find you! Check out all the jobs and post your resume.
The private placement was carried out in accordance with applicable French and U.S. private placement exemptions, and has been made with Capital Ventures International (“CVI”), a U.S. investor, and includes the following securities and terms:
• purchase by the investor of 650,000 new shares (the “New Shares”) (with 650,000 warrants attached) of the Company for a total subscription amount of €10,393,500, representing around 4.85% of the Company’s outstanding shares prior to the private placement;
Help employers find you! Check out all the jobs and post your resume.
